Taken together, these studies highlight the fact that IL-18 may improve immunotherapy only in some cases, and that it depends on the tumor immune-infiltrating cells and their capacity to secrete inhibitory molecules, such as IL-18BP. The gene discussed is IL18; the disease is neoplasm.